Vivus Buys U.S., Canada Rights to Pancreaze from Janssen for $135M

Vivus said today it agreed to acquire U.S. and Canadian rights to the marketed exocrine pancreatic insufficiency treatment Pancreaze ® (pancrelipase) Delayed-Release Capsules from Janssen Pharmaceuticals for $135 million—in what the buyer said was the first in a series of drug acquisitions designed to bolster its finances by growing revenues.Approved in 2010, Pancreaze is a pancreatic enzyme preparation indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibr